Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids.
OBJECTIVE
To characterise and quantify the CD4+ CD25+ T cell population in patients with systemic lupus erythematosus (SLE) and to detect the possible influence of treatments and clinical manifestations.


METHODS
Characterisation of CD25(low) and CD25(high) CD4+ T cells from healthy controls and from patients with SLE was carried out using flow cytometry, analysing the expression of activation and differentiation markers. The percentage of both circulating cell subsets was determined in 56 controls and 110 unselected patients with SLE. Data were related to treatment during the past 3 months and to various clinical manifestations.


RESULTS
CD4+ CD25(high) lymphocytes from controls expressed low levels of CD69, CD154 or CD30, but also expressed glucocorticoid-induced tumour necrosis factor receptor, high levels of intracellular cytotoxin T lymphocyte-associated antigen 4, CD45RO and diminished amounts of CD4, all of which are phenotypic characteristics of natural regulatory T cells. CD4+ CD25(low) cells, on the other hand, expressed the highest levels of activation markers, indicating that they represent recently activated effector cells. Similarly, analysis of cells from patients with SLE showed the same two phenotypically distinguishable CD4+ CD25(low) and CD4+ CD25(high) populations, although both expressed slightly increased levels of activation markers. Quantitative analysis showed a considerably raised percentage of CD25(low) and, especially, CD25(high) cells in patients with SLE compared with controls. This increment was unrelated to clinical manifestations, but correlated with glucocorticoid treatment. Patients treated with glucocorticoids presented raised levels of CD25(high) cells, whereas untreated patients and those with anti-malarial or immunosuppressive drugs had levels similar to those in controls.


CONCLUSIONS
The percentage of CD4+ CD25(high) cells was not altered in non-steroid-treated patients, whereas glucocorticoid treatment increased their frequency in patients with SLE.
Suárez
A
A
Department of Functional Biology, Area of Immunology, University of Oviedo, Oviedo, Spain.
López
P
P
Gómez
J
J
Gutiérrez
C
C
D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000097:blood*; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology*
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2